Gal-3 blocks the binding between PD-1 and pembrolizumab (brand name: Keytruda)

One of the first reports of cDC1 cells related to responders patients to checkpoint blockade immunotherapy

Irreversible electroporation augments β-glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinom (Apr 2023)

Researchers develop a small molecule that could make immunotherapy available to all cancer patients: Researchers have identified and synthesized a small molecule that could be a more accessible and effective alternative to an antibody that is successfully used to treat a range of cancers.

Oxford's cancer vaccine/immunotherapy combo to head for human trials